Elite Pharmaceuticals has signed a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals, Inc., USA to market two Elite generic products in the U.S. with the option to add products in the future.  Glenmark will sell and distribute the products and Elite will receive manufacturing and license fees. Glenmark will have semi-exclusive marketing rights to the ANDA approved product, phendimetrazine 35 mg tablets and exclusive marketing rights to an undisclosed pain product, cur...